Successful treatment of non-midline primary malignant germ cell tumors with yolk sac components in neonates: report of 2 cases

J Neurosurg Pediatr. 2020 Oct 30;27(1):47-51. doi: 10.3171/2020.6.PEDS19719. Print 2021 Jan 1.

Abstract

Here, the authors present 2 cases of nongerminomatous germ cell tumor (NGGCT): a neonate with a mixed malignant germ cell tumor, 5% yolk sac tumor (YST) and 95% immature teratoma components, originating from the right mesial temporal lobe; and a 2-month-old infant with a pure YST originating from the left middle cranial fossa. These tumors with yolk sac components, which are thought to have a poor prognosis, were successfully treated with complete tumor resection alone and subtotal tumor resection with chemotherapy, respectively. Event-free survival exceeds 5 years for each patient even though neither received radiotherapy. The authors highlight the role of radical surgery and the successful treatment of neonatal YST with aggressive resection (and chemotherapy in 1 case) while avoiding radiation therapy. They also report the very rare non-midline location of these neonatal NGGCTs and emphasize the importance of considering YSTs and mixed NGGCTs with YST components in the differential diagnosis of non-midline hemispheric or skull base tumors in newborns.

Keywords: alpha-fetoprotein; chemotherapy; mixed germ cell tumor; nongerminomatous germ cell tumor; oncology; yolk sac tumor.

Publication types

  • Case Reports

MeSH terms

  • Brain Neoplasms / diagnostic imaging
  • Brain Neoplasms / surgery*
  • Cranial Fossa, Middle / diagnostic imaging
  • Cranial Fossa, Middle / surgery*
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Neoplasms, Germ Cell and Embryonal / diagnostic imaging
  • Neoplasms, Germ Cell and Embryonal / surgery*
  • Skull Base Neoplasms / diagnostic imaging
  • Skull Base Neoplasms / surgery*
  • Temporal Lobe / diagnostic imaging
  • Temporal Lobe / surgery*
  • Treatment Outcome
  • Yolk Sac / diagnostic imaging
  • Yolk Sac / surgery*